★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Roche Holding AG
ROG · SIX Swiss Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Roche Holding AG is a Swiss healthcare group with two main divisions: Pharmaceuticals and Diagnostics. Q1 2026 sales were about 78% Pharmaceuticals and 22% Diagnostics. Pharmaceuticals is supported by product-level intellectual property and a large R&D engine, with FY2025/Q1 2026 growth driven by medicines such as Phesgo, Xolair, Ocrevus, Hemlibra and Vabysmo, but faces patent cliffs and pricing pressure. Diagnostics is reinforced by cobas installed-base pull-through, 31bn tests delivered in 2025, digital workflow integration, and regulated assay approvals. Moat durability depends on pipeline productivity, reimbursement, biosimilar erosion, diagnostics tendering, and regulation.
Primary segment
Pharmaceuticals
Market structure
Competitive
Market share
—
HHI: —
Coverage
2 segments · 8 tags
Updated 2026-07-01
Segments
Pharmaceuticals
Innovative (branded) prescription pharmaceuticals
Revenue
77.9%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Diagnostics
In vitro diagnostics platforms, assays and digital laboratory workflow solutions
Revenue
22.1%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Moat Claims
Pharmaceuticals
Innovative (branded) prescription pharmaceuticals
Revenue share uses Q1 2026 sales: Pharmaceuticals CHF 11,469m out of Roche Group CHF 14,722m.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents/exclusivity protect key medicines; when they expire, biosimilar/generic entry drives revenue erosion.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Loss of exclusivity (patent cliffs) on major products
- Biosimilar/generic substitution and tendering
- Government price controls and reference pricing
Leading indicators
- Revenue concentration in products within ~3 years of LOE
- Biosimilar penetration rates for key molecules
- Net price realization trends (gross-to-net, price cuts)
Counterarguments
- The IP moat is temporary at the molecule level; competitors can leapfrog with better efficacy/safety
- Payers can reduce pricing power even before LOE via rebates, formularies and reference pricing
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
Large, sustained R&D investment and modern research infrastructure support a broad pipeline and portfolio renewal.
Capex Knowhow Scale moat: definition, examples, and stocks
Erosion risks
- Diminishing returns on R&D spend / lower R&D productivity
- Talent competition in key modalities (AI/biotech)
- Disruptive platform shifts (e.g., new modalities) where incumbents lag
Leading indicators
- Number of Phase II/III assets and new molecular entities launched
- R&D spend allocation shifts and portfolio prioritisation
- Share of sales from newer medicines vs legacy portfolio
Counterarguments
- Large R&D budgets do not guarantee breakthroughs; smaller biotechs can outperform on innovation per dollar
- External innovation increasingly matters; incumbents may need costly acquisitions to stay current
Diagnostics
In vitro diagnostics platforms, assays and digital laboratory workflow solutions
Revenue share uses Q1 2026 sales: Diagnostics CHF 3,253m out of Roche Group CHF 14,722m. Q1 2026 sales grew 3% at CER and declined 7% in CHF, with core lab and pathology growth offsetting healthcare pricing reforms in China.
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
Large installed instrument base drives recurring assay/test volume (pull-through), supporting repeatable consumables revenue and customer stickiness.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Price pressure via tenders and hospital procurement cycles
- Customers adopting multi-vendor strategies to reduce dependence
- Technology shifts that reduce demand for central lab testing
Leading indicators
- Analytical units placed (cobas pro/pure) and active installed base
- Test volumes and assay menu expansion on installed platforms
- Customer retention/renewal outcomes at contract refresh
Counterarguments
- Large labs can switch platforms at refresh if switching costs are outweighed by price/performance gains
- Some assays are commoditised and can be sourced competitively despite platform lock-in
Data Workflow Lockin
Demand
Data Workflow Lockin
Strength
Durability
Confidence
Evidence
Integration of instruments, automation and digital analytics into lab operations increases workflow switching costs and supports share retention.
Data Workflow Lockin moat: definition, examples, and stocks
Erosion risks
- Third-party middleware/LIS interoperability reduces vendor lock-in
- Open standards and competitor integrations improve portability
- IT/security incidents undermine trust in digital workflow products
Leading indicators
- Adoption of digital solutions (e.g., navify) among installed base customers
- Interoperability requirements (regulatory or customer-driven)
- Share losses/wins in large reference-lab tenders
Counterarguments
- Many labs already operate with independent LIS/middleware; vendor software may be optional
- Integration value may be competed away if rivals offer similar end-to-end workflows
Regulated Standards Pipe
Legal
Regulated Standards Pipe
Strength
Durability
Confidence
Evidence
Ability to win regulatory clearances and quality approvals (FDA/CE/WHO) enables broad assay launches and supports customer trust.
Regulated Standards Pipe moat: definition, examples, and stocks
Erosion risks
- Regulatory tightening (e.g., EU IVDR) increases cost and slows launches
- Product recalls or compliance failures
- Competitors achieving similar approvals rapidly
Leading indicators
- Number of new assay/platform clearances and designations per year
- Regulatory warning letters/recalls
- Time-to-clearance for priority tests
Counterarguments
- Regulatory pathways are available to all capable competitors; it is not exclusive protection
- Incremental assay approvals may not translate to sustained market power if pricing is tender-driven
Evidence
Sales of products with expired patents ... decreased by a combined CHF 0.1 billion at CER
Shows explicit revenue impact when exclusivity ends, implying prior patent-based protection.
Sales of products with expired patents ... decreased by a combined CHF 0.7 billion
Confirms ongoing competitive pressure from biosimilars/generics once protected products face entry.
R&D core investments: CHF 12.2 billion
Scale of R&D spending indicates ability to fund multiple programs and platforms simultaneously.
advanced ten potentially life-changing new medicines into final development
Indicates portfolio renewal breadth from the R&D engine.
Positive data for: fenebrutinib ... Gazyva/Gazyvaro ... and petrelintide
Q1 2026 clinical readouts support the pipeline-productivity thesis across multiple therapeutic areas.
Showing 5 of 11 sources.
Risks & Indicators
Erosion risks
- Loss of exclusivity (patent cliffs) on major products
- Biosimilar/generic substitution and tendering
- Government price controls and reference pricing
- Pipeline clinical failures or safety signals
- Diminishing returns on R&D spend / lower R&D productivity
- Talent competition in key modalities (AI/biotech)
Leading indicators
- Revenue concentration in products within ~3 years of LOE
- Biosimilar penetration rates for key molecules
- Net price realization trends (gross-to-net, price cuts)
- Late-stage pipeline readouts and approval cadence
- Number of Phase II/III assets and new molecular entities launched
- R&D spend allocation shifts and portfolio prioritisation
Research ROG elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.